These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 37723846)

  • 1. The efficacy and safety of chemo-free therapy in epidermal growth factor receptor tyrosine kinase inhibitor-resistant advanced non-small cell lung cancer: A single-arm, phase II study.
    Zhang S; Yang L; Yang Y; Yang G; Xu H; Niu X; Wang Y
    Cancer Med; 2023 Oct; 12(19):19438-19448. PubMed ID: 37723846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study.
    Yin X; Liu X; Ren F; Meng X
    Cancer Immunol Immunother; 2024 May; 73(7):134. PubMed ID: 38758372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance.
    Li Y; Jiang H; Qian F; Chen Y; Zhou W; Zhang Y; Lu J; Lou Y; Han B; Zhang W
    Front Immunol; 2023; 14():1161718. PubMed ID: 37266427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
    Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
    Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study.
    Hayashi H; Chiba Y; Sakai K; Fujita T; Yoshioka H; Sakai D; Kitagawa C; Naito T; Takeda K; Okamoto I; Mitsudomi T; Kawakami Y; Nishio K; Nakamura S; Yamamoto N; Nakagawa K
    Clin Lung Cancer; 2017 Nov; 18(6):719-723. PubMed ID: 28623122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A Real-world Study on the Expression Characteristics of PD-L1 in Patients 
with Advanced EGFR Positive NSCLC and Its Relationship with the 
Therapeutic Efficacy of EGFR-TKIs].
    Chen R; Gao X; Xu F; Zhang S; Ma L; Hu B
    Zhongguo Fei Ai Za Zhi; 2023 Mar; 26(3):217-227. PubMed ID: 37035884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.
    Mok T; Nakagawa K; Park K; Ohe Y; Girard N; Kim HR; Wu YL; Gainor J; Lee SH; Chiu CH; Kim SW; Yang CT; Wu CL; Wu L; Lin MC; Samol J; Ichikado K; Wang M; Zhang X; Sylvester J; Li S; Forslund A; Yang JC
    J Clin Oncol; 2024 Apr; 42(11):1252-1264. PubMed ID: 38252907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tislelizumab plus chemotherapy for patients with
    Zhong H; Zhang X; Tian P; Chu T; Guo Q; Yu X; Yu Z; Li Y; Chen L; Liu J; Zhang Y; Guan Y; Shi X; Wang J; Zhao Y; Han B
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37597849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and influencing factors of immunotherapy combined with chemotherapy and bevacizumab in patients with non-small cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitors treatment failure].
    Wang C; Li Y; Guan Y; Yang SJ; Yin JC; Zhang CF; Guo QS; Shi WN
    Zhonghua Yi Xue Za Zhi; 2023 Apr; 103(16):1210-1216. PubMed ID: 37087404
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
    Akamatsu H; Toi Y; Hayashi H; Fujimoto D; Tachihara M; Furuya N; Otani S; Shimizu J; Katakami N; Azuma K; Miura N; Nishino K; Hara S; Teraoka S; Morita S; Nakagawa K; Yamamoto N
    JAMA Oncol; 2021 Mar; 7(3):386-394. PubMed ID: 33410885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anlotinib plus chemotherapy for T790M-negative EGFR-mutant non-sqNSCLC resistant to TKIs: A multicenter phase 1b/2 trial.
    Li J; Tian Y; Zheng M; Ge J; Zhang J; Kong D; Chen M; Yu P
    Thorac Cancer; 2022 Dec; 13(24):3496-3503. PubMed ID: 36346139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anlotinib or platinum-pemetrexed as second-line therapy in EGFR T790M-negative lung cancer.
    Zhong RB; Xu JL; Lou YQ; Chu TQ; Zhong H; Han BH
    Ann Palliat Med; 2020 Jul; 9(4):1681-1687. PubMed ID: 32575999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study.
    Lu S; Zhang Y; Zhang G; Zhou J; Cang S; Cheng Y; Wu G; Cao P; Lv D; Jian H; Chen C; Jin X; Tian P; Wang K; Jiang G; Chen G; Chen Q; Zhao H; Ding C; Guo R; Sun G; Wang B; Jiang L; Liu Z; Fang J; Yang J; Zhuang W; Liu Y; Zhang J; Pan Y; Chen J; Yu Q; Zhao M; Cui J; Li D; Yi T; Yu Z; Yang Y; Zhang Y; Zhi X; Huang Y; Wu R; Chen L; Zang A; Cao L; Li Q; Li X; Song Y; Wang D; Zhang S; Ding L; Zhang L; Yuan X; Yao L; Shen Z
    J Thorac Oncol; 2022 Oct; 17(10):1192-1204. PubMed ID: 35724798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
    Soo RA; Han JY; Dafni U; Cho BC; Yeo CM; Nadal E; Carcereny E; de Castro J; Sala MA; Bernabé R; Coate L; Provencio Pulla M; Garcia Campelo R; Cuffe S; Hashemi SMS; Früh M; Massuti B; Garcia-Sanchez J; Dómine M; Majem M; Sanchez-Torres JM; Britschgi C; Pless M; Dimopoulou G; Roschitzki-Voser H; Ruepp B; Rosell R; Stahel RA; Peters S;
    Ann Oncol; 2022 Feb; 33(2):181-192. PubMed ID: 34839016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.
    Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Su KY; Chang YL; Wu CT; Hsu CC; Liao BC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
    Eur J Cancer; 2020 Jan; 124():110-122. PubMed ID: 31760310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non-small-cell lung cancer with an EGFR/TP53 co-mutation.
    Shang K; Huang H; Xu Y; Liu Y; Lu Z; Chen L
    BMC Cancer; 2022 Dec; 22(1):1295. PubMed ID: 36503478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting.
    Wang Q; Gao W; Gao F; Jin S; Qu T; Lin F; Zhang C; Zhang J; Zhang Z; Chen L; Guo R
    BMC Cancer; 2021 May; 21(1):602. PubMed ID: 34034713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors.
    Lin L; Pan H; Li X; Zhao C; Sun J; Hu X; Zhang Y; Wang M; Ren X; Luo X; Shan G; Hui AM; Wu Z; Liu H; Tian L; Shi Y
    Lung Cancer; 2022 Apr; 166():98-106. PubMed ID: 35248866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.